-
In this paper, the authors present data from the Valsartan in Acute Myocardial Infarction Trial (VALIANT) on the circumstances and outcomes of cardiac arrest after myocardial infarction (MI).
-
Percutaneous transcatheter aortic valve implantation (TAVI) is an emerging technique for the treatment of aortic stenosis (AS). By this method, a bioprosthetic valve (bovine pericardium) attached to a stent can be deployed in the aortic valve position via a catheter delivery system inserted through either the femoral artery or via the apex of the left ventricle. This technique is available in Europe and is being considered by the FDA for release in the United States.
-
The benefits of cardiac rehabilitation following myocardial infarction (MI) are well known. However, whether these benefits are also seen in ambulant community-based patients who undergo percutaneous coronary intervention (PCI) is not known.
-
The use of aspirin for the primary prevention of cardiovascular (CV) disease remains controversial. In this publication, Bartolucci updates his 2006 meta-analysis by adding three new trials to the six previous ones.
-
-
FDA issues multiple drug safety alerts; ARBs and cancer risk; and FDA actions.
-
ACEI/ARB therapy for AS; safety alert issued for dronedarone; statins and cancer risk; nesiritide and heart failure; and FDA actions.
-
-
Cardiac resynchronization therapy (CRT) is now accepted as a disease-modifying therapy in patients with heart failure, left ventricular dysfunction, and intraventricular conduction defects. In this paper, Sipahi and colleagues review the data on the benefits of CRT in relationship to baseline QRS duration.
-
High-dose loop diuretics are often necessary to reduce elevated filling pressures in patients with heart failure. However, they are known to activate neurohormonal mechanisms that may be harmful.
